SOLID DOSAGE FORM DEVELOPMENT OF GLIBENCLAMIDE WITH INCREASING THE SOLUBILITY AND DISSOLUTION RATE USING COCRYSTALLIZATION
Objective: The aim of this study was to develop a solid dosage form of glibenclamide with increasing the solubility properties of glibenclamide with cocrystallization method.
Methods: Virtual screening was performed to investigate the interaction between glibenclamide and a co-former. Saccharin, the selected co-former, then co-crystallized with glibenclamide with equimolar ratios of 1:1 and 1:2 using the solvent evaporation method. Further characterization was performed using an infra-red (IR) spectrophotometer, differential scanning calorimetry (DSC), and powder x-ray diffraction (PXRD).
Results: Co-crystals of 1:2 equimolar ratio were more highly soluble compared to pure glibenclamide (30-fold for 12 h and 24-fold for 24 h). The dissolution rate had also increased from 46.838% of pure glibenclamide to 77.655% of glibenclamide co-crystal in 60 min. There was no chemical reaction observed during the co-crystallization process based on the IR spectrum. However, there was a new peak in the X-Ray diffractogram and a reduction of melting point in the DSC curve, indicating the formation of co-crystals.
Conclusion: The optimal co-crystal ratio of glibenclamide-saccharin was found to be 1:2, which was successful in improving the solubility of glibenclamide.
2. Rehder SC. Solid-state transformations induced by pharmaceutical processes during manufacturing; 2013.
3. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins: basic science and product development. J Pharm Pharmacol 2010;62:1607â€“21.
4. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 2004;284:109â€“22.
5. Singh A, Worku ZA, Van den Mooter G. Oral formulation strategies to improve solubility of poorly water-soluble drugs. Expert Opin Drug Delivery 2011;8:1361â€“78.
6. Serajuddin ATM. Salt formation to improve drug solubility. Adv Drug Delivery Rev 2007;59:603â€“16.
7. Schultheiss N, Newman A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des 2009;9:2950â€“67.
8. Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004;58:173â€“82.
9. Stella VJ, He Q. Cyclodextrins. Toxicol Pathol 2008;36:30â€“42.
10. Stephenson GA, Aburub A, Woods TA. Physical stability of salts of weak bases in the solidâ€state. J Pharm Sci 2011;100:1607â€“17.
11. Muchow M, Maincent P, MÃ¼ller RH. Lipid nanoparticles with a solid matrix (SLNÂ®, NLCÂ®, LDCÂ®) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394â€“405.
12. Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 2007;65:259â€“69.
13. Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Delivery Rev 2004;56:335â€“47.
14. Gullapalli RP. Soft gelatin capsules (softgels). J Pharm Sci 2010;99:4107â€“48.
15. Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicol Pathol 2008;36:21â€“9.
16. Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug deliveryâ€“an update. Int J Pharm 2018;535:379â€“92.
17. He G, Jacob C, Guo L, Chow PS, Tan RBH. Screening for cocrystallization tendency: the role of intermolecular interactions. J Phys Chem B 2008;112:9890â€“5.
18. Samie A, Desiraju GR, Banik M. Salts and cocrystals of the antidiabetic drugs gliclazide, tolbutamide, and glipizide: solubility enhancements through drug-coformer interactions. Cryst Growth Des 2017;17:2406â€“17.
19. Sopyan, I, Fudholi A, Muchtaridi M, Puspitasari I. A novel of cocrystalization, to improve solubility and dissolution rate of simvastatin. Int J PharmTech Res 2016;9:483â€“91.
20. Gozali D, Megantara S, Levita J, Bahti HH, Soewandhi SN, Abdassah M. Virtual screening of coformers for atorvastatin co-crystallization and the characterizations of the co-crystals. Int J Pharm Sci Res 2016;7:1450â€“5.
21. Siswandi S, Rusdiana T, Levita J. Virtual screening of co-formers for ketoprofen co-crystallization and the molecular properties of the co-crystal. J Appl Pharm Sci 2015;5:78â€“82.
22. Qiao N, Li M, Schlindwein W, Malek N, Davies A, Trappitt G. Pharmaceutical cocrystals: an overview. Int J Pharm 2011; 419:1â€“11.
23. Gianotto EA dos S, Arantes RP, Lara-Filho MJ, Casimiro Filho ACS, Fregonezi-Nery MM. Dissolution test for glibenclamide tablets. Quim Nova 2007;30:1218â€“21.
24. Jouyban A. Handbook of solubility data for pharmaceuticals. CRC Press; 2009.
25. Purwantoro DU, Nugrahani I, Surantaatmadja SI. Studies of preparation, characterization, and solubility of mefenamic acid-nicotinamide co-crystal synthesized by using melt crystallization method. Asian J Pharm Clin Res 2017;10:135-9.
26. Machiste EO, Giunchedi P, Setti M, Conte U. Characterization of carbamazepine in systems containing a dissolution rate enhancer. Int J Pharm 1995;126:65â€“72.
27. Musumeci D, Hunter CA, Prohens R, Scuderi S, McCabe JF. Virtual cocrystal screening. Chem Sci 2011;2:883â€“90.
28. Melandri S. Union is a strength: how weak hydrogen bonds become stronger. Phys Chem Chem Phys 2011;13:13901â€“11.
29. Arunan E, Desiraju GR, Klein RA, Sadlej J, Scheiner S, Alkorta I, et al. Definition of the hydrogen bond (IUPAC Recommendations 2011). Pure Appl Chem 2011;83:1637â€“41.
30. Jayasankar A, Somwangthanaroj A, Shao ZJ, RodrÃguez-Hornedo N. Cocrystal formation during cogrinding and storage is mediated by amorphous phase. Pharm Res 2006;23:2381â€“92.
31. Vishweshwar P, McMahon JA, Bis JA, Zaworotko MJ. Pharmaceutical coâ€crystals. J Pharm Sci 2006;95:499â€“516.
32. Wouters J, Quere L. Pharmaceutical salts and co-crystals. Royal Soc Chem; 2011. p. 391.
33. Rodriguez Hornedo N, Nehm SJ, Jayasankar A. Cocrystals: design, properties and formation mechanisms. In: Swarbrick J. editor. Encycl. Pharm. Technol. Vol. 1. 3rd editio. New York: Informa Healthcare USA, Inc.; 2007. p. 615â€“35.
34. Patel PA, Chaulang GM, Akolkotkar A, Mutha SS, Hardikar SR, Bhosale AV. Self emulsifying drug delivery system: a review. Res J Pharm Technol 2008;1:313â€“23.
35. Ivanisevic I, McClurg RB, Schields PJ. Uses of X-ray powder diffraction in the pharmaceutical industry. In: Gad SC. editor. Pharm Sci Encycl 2010. Doi:10.1002/9780470571224.pse414.
36. Prohens Lopez R, Puigjaner Vallet MC. Crystal engineering studies: polymorphs and co-crystals. Handb Instrum Tech Mater Chem Biosci Res Barcelona: Centres CientÃfics i TecnolÃ²gics. Universitat de Barcelona; 2012.
37. Raghuram M, Alam MS, Prasad M, Khanduri CH. Pharmaceutical cocrystal of prulifloxacin with nicotinamide. Int J Pharm Pharm Sci 2014;6:180â€“4.